Cargando…
Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase
α-Glucosidase as a carbohydrate-hydrolase enzyme is a crucial therapeutic target for type 2 diabetes. In this work, benzo[d]imidazole-amide containing 1,2,3-triazole-N-arylacetamide derivatives 8a–n were synthesized and evaluated for their inhibitory activity against α-glucosidase. In vitro α-glucos...
Autores principales: | Yousefnejad, Faeze, Mohammadi-Moghadam-Goozali, Mahyar, Sayahi, Mohammad Hosein, Halimi, Mohammad, Moazzam, Ali, Mohammadi-Khanaposhtani, Maryam, Mojtabavi, Somayeh, Asadi, Mehdi, Faramarzi, Mohammad Ali, Larijani, Bagher, Amanlou, Massoud, Mahdavi, Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390517/ https://www.ncbi.nlm.nih.gov/pubmed/37524733 http://dx.doi.org/10.1038/s41598-023-39424-8 |
Ejemplares similares
-
Design, synthesis, in vitro, and in silico biological evaluations of coumarin-indole hybrids as new anti-α-glucosidase agents
por: Niri, Davood Rezapour, et al.
Publicado: (2022) -
Design, synthesis, and in silico studies of quinoline-based-benzo[d]imidazole bearing different acetamide derivatives as potent α-glucosidase inhibitors
por: Noori, Milad, et al.
Publicado: (2022) -
Indole-carbohydrazide linked phenoxy-1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro α-glucosidase inhibition, and computational studies
por: Emadi, Mehdi, et al.
Publicado: (2023) -
Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole-N-phenyl (or benzyl) acetamides as potential anti-diabetic agents
por: Emadi, Mehdi, et al.
Publicado: (2023) -
Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
por: Askarzadeh, Mohammad, et al.
Publicado: (2022)